BRCA1 mutations in CRC often result in loss of heterozygosity (LOH), have been found in almost 50% of sporadic cases [16], and offer similar utility as a biomarker for worse outcomes [18, 19] although conflicting results have been reported [16]. This evidence concerns the gene BRCA1 and colorectal carcinoma.